Evolutec study to compare rEV131 and prednisolone in treatment of post-operative eye inflammation

By Lisa Kerner

Charlotte, N.C., June 20 - Evolutec Group plc said it began a 150-patient, double-blind, proof-of-concept phase 2 trial with its lead compound, rEV131, in the treatment of inflammation following cataract surgery.

The trial will compare twice-daily dosing of rEV131 to prednisolone, dosed four times a day, and a placebo over a two-week period.

The primary endpoints of the trial are flare and cell counts. Results are expected by the end of the year.

Taking place at 10 ophthalmic surgical centers in the United States, this trial follows a successful preclinical study showing rEV131 to be as effective as prednisolone 1.0%.

Evolutec believes the value of the post-cataract surgery inflammation market to be about $500 million.

Based in Reading, U.K., Evolutec is a clinical-stage biopharmaceutical company specializing in allergy, inflammation and autoimmune diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.